Superworth

XBiotech profit margin XBIT

Gross, operating and net profit as a share of revenue over the last twelve months, from 2020.

Net margin, 12 months
n/m
a quarter missing
Peer median
11.6%

XBiotech's net margin over the last twelve months can't be worked out yet: a quarter of its results is missing from our data.

Profit margin over time

GrossOperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating marginGross margin
FY2025n/an/an/a
FY2024n/an/an/a
FY2023n/an/an/a
FY2022n/an/a83.8%
FY2021−94.7%n/a68.4%
FY2020−25.5%−41.5%21.5%
FY2019n/an/an/a
FY2018n/an/an/a
FY2017n/an/an/a
FY2016n/an/an/a
FY2015n/an/an/a
FY2014n/an/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a year
Q2 FY26n/an/a
Q1 FY26n/an/a
Q4 FY25n/an/a
Q3 FY25n/an/a
Q2 FY25n/an/a
Q1 FY25n/an/a
Q4 FY24n/an/a
Q3 FY24n/an/a
Q2 FY24n/an/a
Q1 FY24n/an/a
Q4 FY23n/an/a
Q3 FY23n/an/a

Against its peers

Companies in Drug Manufacturers - General nearest XBiotech's size, closest first, today.

CompanyProfit margin
XBITXBiotechn/m
SPROSpero Therapeutics15.7%
ATNMActinium Pharmaceuticalsn/m
LFVNLifevantage2.8%
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
Peer median11.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on XBiotech

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.